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Abstract
Background: Riboflavin synthase catalyzes the transformation of 6,7-dimethyl-8-ribityllumazine
into riboflavin in the last step of the riboflavin biosynthetic pathway. Gram-negative bacteria and
certain yeasts are unable to incorporate riboflavin from the environment and are therefore
absolutely dependent on endogenous synthesis of the vitamin. Riboflavin synthase is therefore a
potential target for the development of antiinfective drugs.
Results: A cDNA sequence from Schizosaccharomyces pombe comprising a hypothetical open
reading frame with similarity to riboflavin synthase of Escherichia coli was expressed in a
recombinant E. coli strain. The recombinant protein is a homotrimer of 23 kDa subunits as shown
by sedimentation equilibrium centrifugation. The protein sediments at an apparent velocity of 4.1
S at 20°C. The amino acid sequence is characterized by internal sequence similarity indicating two
similar folding domains per subunit. The enzyme catalyzes the formation of riboflavin from 6,7-
dimethyl-8-ribityllumazine at a rate of 158 nmol mg-1 min-1 with an apparent KM of 5.7 microM. 19F
NMR protein perturbation experiments using fluorine-substituted intermediate analogs show
multiple signals indicating that a given ligand can be bound in at least 4 different states. 19F NMR
signals of enzyme-bound intermediate analogs were assigned to ligands bound by the N-terminal
respectively C-terminal folding domain on basis of NMR studies with mutant proteins.
Conclusion: Riboflavin synthase of Schizosaccharomyces pombe is a trimer of identical 23-kDa
subunits. The primary structure is characterized by considerable similarity of the C-terminal and
N-terminal parts. Riboflavin synthase catalyzes a mechanistically complex dismutation of 6,7-
dimethyl-8-ribityllumazine  affording riboflavin and 5-amino-6-ribitylamino-2,4(1H,3H)-
pyrimidinedione. The 19F NMR data suggest large scale dynamic mobility in the trimeric protein
which may play an important role in the reaction mechanism.
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Background
Flavocoenzymes derived from riboflavin (vitamin B2) act
as cofactors for a variety of redox reactions and are indis-
pensable in all cells. Whereas plants and many microor-
ganisms obtain riboflavin by endogenous synthesis,
animals depend on nutritional supply of the vitamin. Cer-
tain bacteria (e.g. Enterobacteriaceae) and yeasts are una-
ble to incorporate riboflavin from the environment and
are therefore absolutely dependent on the endogenous
synthesis of the vitamin [1-4], and the enzymes of the
riboflavin biosynthetic pathway are therefore potential
targets for antiinfective drug design.
The absence of the riboflavin biosynthetic pathway in the
human host is advantageous with regard to drug develop-
ment. The final step in the riboflavin biosynthetic path-
way is catalyzed by riboflavin synthase. The
mechanistically unusual dismutation of the substrate, 6,7-
dimethyl-8-ribityllumazine (Compound 3, Fig. 1) afford-
ing riboflavin (Compound 4) and 5-amino-6-ribit-
ylamino-2,4(1H,3H)-pyrimidinedione (Compound 1)
requires the presence of two substrate molecules serving
as donor resp. acceptor of a 4-carbon moiety at the active
site of the enzyme [5-7]. The regiochemistry of the
enzyme-catalyzed reaction predicts an antiparallel
arrangement of the two substrate molecules [8-10]. A pen-
tacyclic dimer of 6,7-dimethyl-8-ribityllumazine (Com-
pond  5, Fig. 2) has been identified as a kinetically
competent intermediate in the complex reaction sequence
[11]. The riboflavin synthases of Escherichia coli and Bacil-
lus subtilis are homotrimeric proteins [12-14].
Intramolecular sequence similarity suggested that each
subunit folds into two topologically similar domains,
each of which can accommodate one substrate molecule.
The active site was proposed to be located at the interface
of adjacent domains; two substrate molecules were
assumed to be sandwiched between adjacent subunits
[14]. The structure of riboflavin synthase from E. coli as
determined by X-ray crystallography at a resolution of 2.0
Å confirmed the predicted similarity in the folding pat-
terns of the N-terminal and C-terminal domain (rms = 0.8
Å) [15] but gave no direct information on enzyme sub-
strate interaction. The N-terminal domain of the E. coli
enzyme (residues 1 – 97) could be expressed as a stable
protein with a relatively high affinity for riboflavin.
Surprisingly, this artificial protein is a c2  symmetric
homodimer, whereas the full length riboflavin synthase
subunit forms a homotrimer [16]. The structure of the
artificial N-terminal domain dimer in complex with ribo-
flavin has been determined by NMR spectroscopy [17].
Protein perturbation studies monitored by 19F NMR with
fluorine-substituted intermediate analogs had suggested
that the binding sites of the homotrimeric riboflavin syn-
thase are not topologically equivalent [18-20].
More specifically, these experiments showed that certain
ligands could be bound to the protein in at least four dif-
ferent binding states, whereas only two different states
(one for the N-terminal and one for the C-terminal
domain) would have been expected in a c3 symmetric
homotrimer. These observations are well in line with the
absence of trigonal molecular symmetry revealed by the
X-ray structure analysis of riboflavin synthase of E. coli
[15]. The structure of riboflavin synthase from S. pombe in
complex with the substrate analog, 6-carboxyethyl-7-oxo-
8-ribityllumazine has been determined at 2.1 Å resolu-
tion. In contrast to the homotrimeric solution state of
native riboflavin synthase, the enzyme was found to be
monomeric in the crystal structure. Structural comparison
of the riboflavin synthases of S. pombe and E. coli sug-
gested oligomer contact sites and delineated the catalytic
site for dimerization of the substrate and subsequent frag-
mentation of the pentacyclic intermediate [21]. This paper
reports 19F NMR protein perturbation studies using wild
type and mutant riboflavin synthase of S. pombe in com-
plex with fluorinated intermediate analogs. The data sug-
gest large scale domain mobility which appear relevant for
the complex reaction mechanism.
Results
A putative rib5+ gene of S. pombe (NCBI accession number,
T40995) predicted a protein of 208 amino acid residues
with similarity to riboflavin synthase (50 % identity with
riboflavin synthase of S. cerevisiae and 36 % identity with
riboflavin synthase of E. coli).
The open reading frame was amplified from S. pombe
cDNA and was cloned into the plasmid vector pNCO113.
The cDNA sequence as determined by dideoxynucleotide
sequencing was identical with the chromosomal sequence
reported earlier and has been deposited in the GenBank
data base (accession number AF505789).
A recombinant E. coli strain carrying a plasmid with the S.
pombe rib5+ gene under control of the T5 and the lac oper-
ator expressed a protein with an approximate mass of 23
kDa as judged by SDS electrophoresis. The recombinant
protein accounting for about 20 % of cell protein was
purified to apparent homogeneity by three chromato-
graphic steps as described under Methods. Partial Edman
degradation afforded the N-terminal sequence MFT-
GLVEAIGVVKDVQGTID in agreement with the open
reading frame.
The protein shows internal sequence similarity. Twenty
one amino acid residues are identical in the N-terminal
and C-terminal section (Fig. 3).BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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Terminal reactions in the pathway of riboflavin biosynthesis Figure 1
Terminal reactions in the pathway of riboflavin biosynthesis. A, 3,4-dihydroxy-2-butanone 4-phosphate synthase; B, 
6,7-dimethyl-8-ribityllumazine synthase; C, riboflavin synthase.
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Hypothetical reaction mechanism of riboflavin synthase Figure 2
Hypothetical reaction mechanism of riboflavin synthase. X, unkown nucleophile; R, ribityl. [11]BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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The recombinant protein had a specific activity of 158
nmol mg-1 min-1 and an apparent KM of 5.7 µM at pH 7.2
and 37°C (Table 1). Electrospray mass spectrometry
afforded a relative mass of 22,863 Da in good agreement
with the predicted mass of 22,861 Da. The recombinant
protein sediments as a single, symmetrical boundary with
an apparent velocity of 4.1 S. Sedimentation equilibrium
experiments indicate a molecular mass of 74 kDa using an
ideal monodisperse model for simulation. Sedimentation
equilibrium analysis in the presence of 5 mM 6-carboxye-
thyl-7-oxo-8-D-ribityllumazine (Compound 8; Fig. 4)
afforded an apparent molecular weight of 76 kDa. It fol-
lows that the enzyme is homotrimer like the riboflavin
synthases of B. subtilis and E. coli [13,22] and that the qua-
ternary structure is not affected by binding of the substrate
analog.
Protein perturbation studies monitored by 19F NMR had
been performed earlier with riboflavin synthases from B.
subtilis and E. coli and had shown surprising multiplicities
of signals for enzyme-bound ligands [18-20,23]. Thus,
studies with the intermediate analog, 6-trifluoromethyl-7-
oxo-8-ribityllumazine (Compound 7, Fig. 4) had sug-
gested at least four different binding states characterized
by different 19F signals spread over a range of about 9
ppm, and the covalent hydrate of 6,7-bis(trifluorome-
thyl)-8-ribityllumazine (Compound 6a, epimer A) could
be bound in at least two different states. On the other
hand, lumazine protein from Photobacterium phosphoreum,
a monomeric paralog of riboflavin synthase without
enzyme activity which serves as an optical transponder in
bioluminescence showed single signals for each trifluor-
omethyl group of lumazine analogues [24,25]. Similarly,
an artificial N-terminal domain of E. coli riboflavin syn-
thase which forms a c2 symmetric homodimer showed
single lines for each trifluoromethyl group of trifluor-
omethylsubstituted lumazine derivatives [16].
Intramolecular sequence similarity of S. pombe riboflavin synthase Figure 3
Intramolecular sequence similarity of S. pombe riboflavin synthase. N-terminal part, amino acids 1–97; C-terminal 
part, amino acids 98–208. Identical residues are coloured black. The residues subjected to mutagenesis in this study are 
marked by an arrow.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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Figs. 5 and 6 show comparative protein perturbation
experiments with various orthologs and paralogs of the S.
pombe enzyme including lumazine protein (Figs. 5A, 6A),
the N-terminal domain of E. coli riboflavin synthase (Figs.
5B, 6B) and full length riboflavin synthases of different
organisms (Figs. 5C,5D,5E, 6C,6D,6E). All spectra were
recorded in the present study under identical experimen-
tal conditions.
The monotrifluoromethyl derivative, Compound 7, in
complex with riboflavin synthase of S. pombe shows four
signals at 8.8, 10.9, 15.6 and 16.0 ppm (Fig. 5E). The sig-
nal of the free ligand resonates at 7.7 ppm (indicated by a
dashed line in Fig. 5) with a line width of 56 Hz, whereas
the signals of the ligand bound in different states had
apparent line widths extending from 90 to approximately
540 Hz. The riboflavin synthases of E. coli (Fig. 5C) and B.
subtilis (Fig. 5D) show similar signal multiplicities, but the
chemical shifts and line widths are markedly different. In
stark contrast, lumazine protein (Fig. 5A) and the c2 sym-
metric N-terminal domains of E. coli riboflavin synthase
(Fig. 5B) show single and much narrower lines for the
protein bound ligand. It is immediately obvious that a
given ligand can be bound in multiple, significantly dif-
ferent states by all riboflavin synthases studied, but only
in a single state by lumazine protein or the artificial, c2
symmetric N-terminal domain.
A similar set of experiments with the bistrifluoromethyl
analog 6a of 6,7-dimethyl-8-ribityl-lumazine is shown in
Fig. 6. Due to the presence of six fluorine atoms, the
lumazine derivative forms two stable diastereomeric
hydrates 6a and 6b which differ by their configuration at
the ring carbon atom 7 and are not subject to racemiza-
tion or dehydration. The stereochemical assignments
shown in Fig. 4 were suggested on basis of solid-state
NMR studies [26,27].
As shown in Fig. 6A,6B, lumazine protein and the dimeric
N-terminal domain of E. coli riboflavin synthase show sin-
gle lines for each trifluoromethyl group of bound Com-
pound 6a. In contrast to that, the riboflavin synthases
(Figs. 6C,6D,6E) studied show multiple signals, and the
signal patterns are highly variable for enzymes from dif-
ferent species. The enzyme of S. pombe (Fig. 6E) shows the
most complex picture with three major signals for the
position 7 trifluoromethyl group and two major signals
for the position 6 trifluoromethyl group of the ligand in
the bound state. The signals of the free epimer A appeared
broadened to 80 Hz – 100 Hz, whereas the signals of the
ligand bound in different states had apparent line widths
of 170 – 300 Hz.
In an earlier study, we reported 19F protein perturbation
studies obtained with a series of mutants of E. coli ribofla-
vin synthase [18]. In that study, it was not possible to
express mutant proteins characterized by replacement of
the conserved cysteine 48 which is located close to the
bound riboflavin in the artificial N-terminal domain
dimer [17]. Since a catalytic role had been proposed for
that residue [17], a renewed mutagenesis attempt was
made with the S. pombe protein. In contrast to our earlier
findings with the E. coli enzyme, cystein 48 of the S. pombe
enzyme could be replaced by various amino acids, and the
proteins could be expressed to high levels. Similarly,
mutant proteins with the topologically equivalent S146
residue in the C-terminal domain (cf. Fig. 3) could be
expressed.
The catalytic properties of the mutants are summarized in
Table 3. Replacement of cystein 48 by serine reduced the
catalytic rate of the enzyme by a factor of about 6; C48A
and C48M mutants had no detectable enzyme activity.
The replacement of serine 146 had only a minor influence
on the catalytic rate, in close similarity with our earlier
Table 1: Bacterial strains and plasmids
Strain or plasmid Relevant characteristics Source
E. coli strain
XL-1-Blue recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac[F', proAB, lacIqZ∆ M15, Tn10(tetr)] 34
M15 [pREP4] lac, ara, gal, mtl, recA+, uvr+, [pREP4: lacI, kanr]4 3
BL21 (DE3) F-, ompT, hsdSB, (r-B, m-B), gal, dcm (DE3) 44
Plasmids
pNCO113 expression vector 36
pT7-7 expression vector 45
pNCO-SSP-Rosy-WT vector expressing the wild type SSP-Rosy this study
pT7-SSP-Rosy-C48S vector expressing a C48S mutated SSP-Rosy this study
pT7-SSP-Rosy-C48A vector expressing a C48A mutated SSP-Rosy this study
pT7-SSP-Rosy-C48M vector expressing a C48M mutated SSP-Rosy this study
pT7-SSP-Rosy-S146A vector expressing a S146A mutated SSP-Rosy this study
pT7-SSP-Rosy-S146C vector expressing a S146S mutated SSP-Rosy this studyBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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Intermediate analogs used for protein perturbation studies Figure 4
Intermediate analogs used for protein perturbation studies. 6,7-bis(trifluoromethyl)-8-ribityllumazine hydrate, epimer 
A (Compound 6a) and epimer B (Compound 6b). 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7). 6-carboxyethyl-7-
oxo-8-ribitylluamzine (Compound 8), 5-nitro-6-ribitylamino-2,4(1H,3H)-pyrimidinedione (Compound 9).
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19F NMR spectra of 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7) Figure 5
19F NMR spectra of 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7). A, lumazine protein of P. leiognathi 
(0.13 mM protein, 0.25 mM 7); B, recombinant N-terminal domain of E. coli riboflavin synthase (0.80 mM protein, 0.98 mM 7); 
C, riboflavin synthase of E. coli (0.37 mM protein, 1.43 mM 7); D, riboflavin synthase of B. subtilis (0.10 mM protein, 0.75 mM 7); 
E, riboflavin synthase of S. pombe (0.28 mM protein, 1.22 mM 7). All samples contained 20 mM phosphate buffer, 100 mM KCl 
and 10% D2O, pH 7. Signals of the free ligand are indicated by a dashed line. The data were processed with a line broadening of 
20 Hz.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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19F NMR signals of 6,7-bis(trifluoromethyl)-8-ribityllumazine hydrate (epimer A; Compound 6a) Figure 6
19F NMR signals of 6,7-bis(trifluoromethyl)-8-ribityllumazine hydrate (epimer A; Compound 6a). A, lumazine 
protein of P. leiognathi (0.14 mM protein, 0.23 mM 6a); B, recombinant N-terminal domain of E. coli riboflavin synthase (0.75 
mM protein, 0.56 mM 6a); C, riboflavin synthase of E. coli (0.5 mM protein, 3.34 mM 6a); D, riboflavin synthase of B. subtilis 
(0.13 mM protein, 0.41 mM 6a); E, riboflavin synthase of S. pombe (0.26 mM protein, 0.60 mM 6a); x, impurities. For other 
details see legend to Fig. 5.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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findings with E. coli riboflavin synthase [18]. The
replacement of cystein 48 had major impact on ligand
perturbation spectra (Fig. 7) with 6-trifluoromethyl-7-
oxo-8-ribityllumazine (Compound 7, Fig. 4). When
cystein was replaced by less bulky residues (alanine, ser-
ine), no 19F NMR signals were noted in the range of 14 –
17 ppm, whereas the wild type protein shows two intense,
closely spaced signals at 15.6 and 16.0 ppm. When cystein
48 was replaced by the more bulky methionine, intense
signals were observed at 13.8 and 14.0 ppm. Notably, the
mutation in the N-terminal domain affects the entire
spectrum rather than individual signals. Although a signal
is consistently observed at about 8.8 ppm, at least its
relative intensity is modulated substantially by the
replacement of cystein 48.
In the C-terminal domain, serine 146 is the topological
equivalent of cystein 48. Although this residue appears to
be absolutely conserved, its replacement by the less bulky
alanine or the more bulky cystein has relatively little influ-
ence on the catalytic rate and the Michaelis constant of the
enzyme. However, the replacement of serine 146 had
major impact on the protein perturbation spectra (Fig. 7).
The signal at 8.8 ppm which is present in the wild type
protein and all cystein 48 mutants has an increased
intensity in case of the S146A mutant but is absent or
shifted in the S146C mutant protein. Again, it should be
noted that the replacement of serine 146 affects the entire
spectrum rather than individual signals.
In line with the other proteins described in this study,
riboflavin synthase of S. pombe binds epimer A believed to
represent the 7-R diasteromer, whereas epimer B (7-S)
showed no detectable interaction (data not shown). The
6-trifluoromethyl groups of 6-trifluoromethyl-7-oxo-8-
ribityl-lumazine and 6,7-bis(trifluoromethyl)-8-ribityl-
lumazine hydrate (epimer A) are topologically equivalent.
The 19F NMR signals assigned to that group in the bistrif-
luoromethyl compound 6a in Figs. 6 and 8 are spread out
over a range of only about 4 ppm, as compared to a range
of 9 ppm in case of the 7-oxo compound 7, but the impact
of mutations is similar. Again, mutation of either cystein
48 or serine 146 affects all signals attributed to bound lig-
ands (Fig. 8).
6,7-Bis(trifluoromethyl)-8-ribityllumazine hydrate
(epimer A) could be displaced from S. pombe protein by
addition of riboflavin or the product analog, 5-nitro-6-
ribitylamino-2,4(1H,3H)-pyrimidinedione (Compound
9, Fig. 4), thus suggesting that each of the signals, assigned
to bound ligand, represented binding sites with specificity
for substrate/intermediate analogs rather than non-spe-
cific protein surface interactions (data not shown). In the
mixture, epimer A displaced from the enzyme by the com-
peting ligands had a linewidth of about 20 Hz.
The complexity of the interaction of the proteins with the
ligands is further illustrated by the titration experiments
shown in Figs. 9 and 10. In the spectra of the wild type
enzyme as well as the C48A mutant, the protein/ligand
ratio affects not only the intensity and the line width of
the different bands assigned to compound 7 in the protein
bound state, but also the chemical shifts of individual sig-
nals. Remarkably, some of the peaks appeared with
smaller line widths in later stages of the titration experi-
ment (cf. peak at about 9 ppm in Fig. 9). This effect could
indicate a combination of substrate induced conforma-
tional changes affecting the dynamics of the protein.
Discussion
Lumazine proteins are paralogs of riboflavin synthase
occurring in luminescent marine bacteria where they are
believed to serve as optical transponders which absorb
energy from bacterial luciferase by Förster transfer and are
conducive to enhanced luminescence quantum yield as
well as modulation of the emission frequency [28,29]. In
Table 2: Oligonucleotide primers used for construction of rib5+ expression plasmid and for site-directed mutagenesis
Primer Primer 
orientation
Amino acid replacement Novel restriction site Sequence (5'– 3')
SSP-RIB5-1 - none EcoRI ATAATAGAATTCATTAAAGAGGAGAAATTAACCATGTTTACC
GGTCTTGTTGAAGCCATTGGTGTTG
SSP-RIB5-2 + none BamHI TATTATGGATCCTCAAGCTTGGGTTTTCTTAATCCAGTC
1 - none (flanking primer) GGTCTAGATCACACAGAATTCATTAAAGAGG
2 + none (flanking primer) GACTGCAGTCAAGCTTGGGTTTTCTTAA
3 + C48 → S HpaI TCTGTCACTGTAAGagAAGTACCGTTaACGGCGATACT
4+ C 4 8   → A HpaI TCTGTCACTGTAAGagcAGTACCGTTaACGGCGATACT
5 + C48 → M HpaI TCTGTCACTGTAAGcatAGTACCGTTaACGGCGATACT
5 - S146 → C KpnI ATAGCCCTGGACGGTACcTgtCTGACCATTACTCAT
6 - S146 → A KpnI ATAGCCCTGGACGGTACcgCGCTGACCATTACTCAT
Oligonucleotides were designed to hybridize to the sense (+) and to the antisense (-) strand of the rib5+. Mutated bases are indicated in lower case. 
Codons specifying modified amino acid residues are shown in bold type. Novel restriction sites are underlined.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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19F NMR spectra of 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7) in the presence of riboflavin synthase mutants of  S. pombe Figure 7
19F NMR spectra of 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7) in the presence of riboflavin syn-
thase mutants of S. pombe. Concentrations in the NMR samples were as follows: C48M, 0.28 mM protein, 1.10 mM 7; 
C48A, 0.15 mM protein, 0.57 mM 7; C48S, 0.15 mM protein, 0.80 mM 7; wild type, 0.28 mM protein, 1.22 mM 7; S146C, 0.20 
mM protein, 0.92 mM 7; S146A, 0.26 mM protein, 1 mM 7. For other details see legend to Fig. 5.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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19F NMR spectra of 6,7-bis(trifluoromethyl)-8-ribityllumazine hydrate (epimer A, Compound 6a) in the presence of riboflavin  synthase mutants of S. pombe Figure 8
19F NMR spectra of 6,7-bis(trifluoromethyl)-8-ribityllumazine hydrate (epimer A, Compound 6a) in the pres-
ence of riboflavin synthase mutants of S. pombe. Concentrations in the NMR samples were as follows: C48M, 0.30 mM 
protein, 0.94 mM 6a; C48A, 0.19 mM protein, 0.33 mM 6a; C48S, 0.20 mM protein, 0.42 mM 6a; wild type, 0.26 mM protein, 
0.60 mM 6a; S146C, 0.26 mM protein, 0.65 mM 6a; S146A, 0.34 mM protein, 1 mM 6a; x, impurities. For other details see leg-
end to Fig. 5.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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19F NMR spectra of 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7) in titration experiments with riboflavin synthase  of S. pombe (wild type) Figure 9
19F NMR spectra of 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7) in titration experiments with 
riboflavin synthase of S. pombe (wild type). The initial concentration of the protein was 0.36 mM. Compound 7 was 
added to the concentrations indicated. The spectra are displayed with equal intensities of the signals at 15.6 ppm (indicated by 
*). For other details see legend to Fig. 5.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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19F NMR spectra of 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7) in titration experiments with C48A mutant of  riboflavin synthase of S. pombe Figure 10
19F NMR spectra of 6-trifluoromethyl-7-oxo-8-ribityllumazine (Compound 7) in titration experiments with 
C48A mutant of riboflavin synthase of S. pombe. The initial concentration of the protein was 0.24 mM. Compound 7 
was added to the concentrations indicated in the spectra. The spectra are displayed with equal intensities of the signals as indi-
cated by *. For other details see legend to Fig. 5.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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contrast to the homotrimeric riboflavin synthase which
can bind up to 6 substrate molecules, lumazine proteins
have been reported to be monomers which bind only one
molecule of 6,7-dimethyl-8-ribityllumazine. Although
they are likely to share the two-domain architecture of the
riboflavin synthase subunit, it appears that only one
domain engages in ligand binding. Notably, all riboflavin
synthases studied as well as lumazine protein are strictly
stereoselective and bind epimer A (Compound 6a, Fig. 4)
but not epimer B (Compound 6b) of the diastereomeric
6,7-bis(trifluoromethyl)-8-ribityllumazine hydrate.
Not surprisingly, when the fluorinated lumazines 6a or 7
are bound to lumazine protein, a single 19F NMR signal is
observed for each respective trifluoromethyl group (Figs.
5A, 6A). Similarly, the c2 symmetric dimer obtained by
recombinant expression of the N-terminal domain of
riboflavin synthase shows a single 19F NMR signal for each
trifluoromethyl group of a bound ligand (Figs. 5B, 6B).
Since both domains of riboflavin synthase can bind lig-
and molecules, one would expect to observe separate sets
of signals for ligands bound to each respective domain.
Beyond that expectation, however, all riboflavin synthases
studied in this paper show multiple signals for each ligand
studied (Figs. 5C,5D,5E, 6C,6D,6E). Moreover, the signal
patterns depend on the ratio of protein and ligand in the
solution in unexpected ways (Figs. 9, 10), and the replace-
ment of an amino acid at the C-terminal or N-terminal
domain ligand binding site affects virtually all signals
attributed to bound ligands. It follows that riboflavin syn-
thase is not c3 symmetric in solution. The asymmetry
revealed by the X-ray structure of the E. coli enzyme [15] is
thus an inherent property of the enzyme and is not due to
crystal contacts.
Based on the NMR experiments with the mutant proteins
obtained by replacement of cystein 48 or serine 146, it is
now possible to assign 19F signals of the bound ligand in
Fig. 7 to the N- or C-terminal domain. Comparison of the
spectra in Fig. 7 suggests that the 19F signals shifted to
lower field represent ligand molecules which are bound to
the N-terminal domain and are therefore predominantly
affected by the modification of cystein 48, whereas the
signals shifted to higher field represent molecules bound
to the C-terminal domain which are more susceptible to
the modification of serine 146. However, it must be
emphasized that all signals are affected at least to some
extent by the mutations.
The X-ray structure of the E. coli enzyme suggests that
direct contact exists only between the ligand binding sites
of one N-terminal domain and the C-terminal domain of
the adjacent subunit [15], whereas the ligand binding
sites of two N-terminal and two C-terminal domains are
exposed to solvent but not to an adjacent protein subunit.
Since a number of studies has indicated that riboflavin
synthase can bind certain ligands at a stoichiometry of 1:6
[18,20,22], we assume that each N-terminal and each C-
terminal domain can participate in ligand binding.
The major difference is a cysteine residue (position 48 in
the N-terminal domain) being replaced by a serine resi-
due (position 146 in the C-terminal domain). Both
amino acids are absolutely conserved in all putative
riboflavin synthase paralogs. Nevertheless, serine 146 of
the S. pombe enzyme can be replaced by alanine with only
a minor impact on enzyme activity. Replacement of
cysteine 48 by serine reduces the activity by a factor of five,
but replacement by alanine affords a soluble protein
whose activity, if any, is below the level of detection. It
should also be noted that mutant genes specifying E. coli
riboflavin synthase mutants carrying alanine or serine
instead of cysteine 48 (corresponding to cysteine 48 of the
S. pombe enzyme) could not be expressed in recombinant
E. coli strains [18]. As seen in the X-ray structure of ribofla-
vin synthase of S. pombe [21] the closest neighbor of the
thiol group at position 48 is the 6-methylene group of the
substrate analog, 6-carboxyethyl-7-oxo-8-ribityllumazine
with a distance of 3.7 A° indicating an essential role of
C48 in the catalytic mechanism of riboflavin synthase.
The riboflavin synthase subunit folds into two domains
with closely similar folding topology. This had been antic-
ipated on the basis of sequence arguments [14] and has
been confirmed by X-ray structure analysis of riboflavin
synthase of E. coli (without bound ligand) [15] and of S.
pombe  (with bound ligand). The monomeric S. pombe
riboflavin synthase model arranged in a distinct N-termi-
nal barrel (residues 1–90), an almost identically folded
distinc C-terminal barrel (residues 91–184), and a C-ter-
minal α-helix [21].
On basis of these structural arguments, one could expect
that ligands bound to C-terminal domains without close
interaction with N-terminal domains should not be influ-
enced by conservative changes in the N-terminal domain.
More specifically, the replacement of sulfur by oxygen in
the C48S mutant should not influence the 19F resonance
of ligands bound at topologically remote C-terminal
domain. The same argument holds vice versa for the influ-
ence of mutations in the C-terminal domain, e.g. the
replacement of oxygen by sulfur in the C-terminal domain
on ligands bound to distant N-terminal domains.
On basis of the finding that, contrary to that hypothesis,
minor modifications of either N-terminal or C-terminal
binding sites can modulate all aspects of the 19F signatures
of the bound ligands, we propose that riboflavin synthase
is subject to large scale dynamic motions occurring on theBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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time scale of the NMR experiments. More specifically, we
propose that the pair of N-terminal and C-terminal
domain in direct contact as observed in the crystal struc-
ture is not permanently associated in solution where the
respective domains of different subunits can temporarily
assume that special relationship by major domain
motions. Previous structural analysis [15] and molecular
modeling revealed a markedly nonsymmetric trimeric
state of riboflavin synthase. The modeling experiments,
based on the inhibitor-bound protein [21], strongly sug-
gest that the close intersubunit contact of the trimer as
seen in the crystals of the E. coli protein is indeed in an
active conformation and capable of supporting the dis-
mutation reaction. Therefore, this trimer very likely repre-
sents a distinct functional state. As there is no reason to
suggest a static asymmetric ensemble, it appears likely that
thermal fluctuation or substrate binding converts the
three different intersubunit contacts into one another,
retaining an asymmetric trimer.
Such a dynamic model would fit the wide variation of line
widths found for the different protein bound states as well
as the unexpected dependence of the 19F NMR spectra on
the molar ratio between protein and ligand as revealed in
Figs. 9 and 10.
Conclusions
The observations on protein dynamics are highly relevant
for the reaction mechanism. Conceivably, the ligand
binding sites of N- and C-terminal domains can be loaded
with substrate while they are out of physical contact with
each other. In order for the dismutation to occur, the
domains could then form the local N-terminal/C-termi-
nal domain complex by motion of the entire protein. The
products could be unloaded after that domain pair has
been separated again by major protein motions, and con-
tacts between other domains could be established which
could also result in product formation. In other words, all
six domains would participate in the dismutation of the
substrate, but they would do so at different times.
A dynamic model involving configuration changes of
riboflavin synthase in the context of the catalytic reaction
has been proposed earlier on basis of competitive ligand
binding [23]. Since the reaction catalyzed by riboflavin
synthase occurs on the time of seconds (the turnover
number of the S. pombe enzyme is 11 min-1 per trimer),
relatively slow dynamic motions occurring on the milli-
second time scale would amply suffice the dynamic
requirements of that slow catalytic reaction.
Methods
Materials
6,7-Dimethyl-8-ribityllumazine [30], 6-trifluoromethyl-
7-oxo-8-ribityllumazine [19], 6-carboxy-ethyl-7-oxo-8-
ribityllumazine [31,32] and 6,7-bis(trifluoromethyl)-8-
ribityllumazine hydrate (epimers A and B) [19] were
prepared by published procedures. Oligonucleotides were
custom synthesized by Interactiva, Ulm, Germany.
Restriction enzymes were from New England Biolabs,
Schwalbach, Germany. T4 DNA ligase and reverse
transcriptase (SuperScriptII) were from Gibco BRL, Eggen-
stein, Germany. Taq Polymerase was from Finnzyme,
Epsoo, Finnland. Vent DNA po-lymerase was purchased
by New England Biolabs, Schwalbach, Germany. DNA
fragments were purified with the QIAquick PCR Purifica-
tion Kit from Qiagen, Hilden, Germany.
Microorganisms and plasmids
Microorganisms and plasmids used in this study are sum-
marized in Table 1.
Proteins
Recombinant riboflavin synthase of E. coli and B. subtilis
were prepared as described earlier [18,23].
Preparation of cDNA
The isolation of RNA from S. pombe var. pombe Lindner
(ATCC 16491) and the preparation of cDNA was per-
formed as described earlier [33].
Construction of the rib5+ expression plasmid
A hypothetical open reading frame (accession number
T40995) was amplified by PCR using S. pombe cDNA as
template and the oligonucleotides SSP-RIB5-1 and SSP-
RIB5-2 (Table 2) as primers. The amplificate was digested
with EcoRI and BamHI and was ligated into the expression
vector pNCO113 which had been digested with the same
enzymes yielding the plasmid designated pNCO-SSP-Rosy-
WT.
Site directed mutagenesis
A procedure described earlier was used for site-directed
mutagenesis [18]. Plasmid pNCO-SSP-Rosy-WT was used
as template. The primers used for mutagenesis are shown
in Table 2.
Transformation of E. coli cells
E. coli XL-1 Blue cells were transformed with ligation mix-
tures by published procedures [34]. Transformants were
selected on LB agar plates supplemented with ampicillin
(170 mg/l). All plasmid constructs were sequenced by the
automated dideoxynucleotide method [35] using a 377
Prism DNA sequencer from Applied Biosystems (Weiters-
tadt, Germany).
pNCO113 type plasmids reisolated from XL-1 Blue cells
were transformed into E. coli M15 [pREP4] [36] cells car-
rying the pREP4 repressor plasmid for the overexpression
of lac repressor protein. Kanamycin (15 mg/l) and ampi-BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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cillin (170 mg/l) were added to secure the maintenance of
both plasmids in the host strain. In the pNCO113 expres-
sion plasmids, the riboflavin synthase variants are under
control of the T5 promotor and the lac operator.
pT7-7 type plasmids reisolated from XL-1 Blue cells were
transformed into E. coli BL21 (DE3) cells. The host strain
contains a T7 RNA polymerase gene under the control of
a lac operator, whereas the riboflavin synthase genes are
under control of the T7 promotor.
Protein purification
Recombinant E. coli strains were grown in LB medium
containing ampicillin (170 mg/l) and kana-mycin (20
mg/l) at 37°C with shaking overnight. Erlenmeyer flasks
containing 500 ml of medium were inoculated at a ratio
of 1:50 and were incubated at 37°C with shaking. At an
optical density of 0.6 (600 nm), IPTG was added to a final
concentration of 2 mM, and incubation was continued for
5 h. The cells were harvested by centrifugation, washed
with 0.9 % NaCl and stored at -20°C. Frozen cell mass (6
g) was thawed in 35 ml of 20 mM potassium phosphate,
pH 7.0. The suspension was subjected to ultrasonic treat-
ment and was then centrifuged (20 min, 15,000 rpm,
4°C). The supernatant was placed on top of a Q-Sepha-
rose column (2.0 × 7.5 cm, Amersham Phar-macia Bio-
tech, Freiburg, Germany) (flow rate, 5 ml min-1) which
had been equilibrated with 200 mM potassium phos-
phate, pH 7.0. The column was developed with a linear
gradient of 0–1.0 M potassium chloride in 20 mM
potassium phosphate, pH 7.0 (total volume, 700 ml).
Fractions were combined and concentrated by ultrafiltra-
tion using Amicon 10 kDa membranes. The solution was
placed on top of a Superdex-200 column (2.6 × 60 cm,
Amersham Pharmacia Biotech, Freiburg, Germany) (flow
rate, 3 ml min-1) which was developed with 20 mM potas-
sium phosphate, pH 7.0, containing 70 mM potassium
chloride. Fractions were combined and placed on top of a
column of Phenyl-Sepharose CL4B (1.5 × 5.5 cm, Amer-
sham Pharmacia Biotech, Freiburg, Germany) (flow rate,
2 ml min-1) which had been equilibrated with 20 mM
potassium phosphate, pH 7.0, containing 500 mM
ammonium sulfate. The column was developed with a
linear gradient of 0–10 % glycerol containing 20 mM
potassium phosphate, pH 7.0 (total volume, 100 ml).
Isolation and purification of lumazine protein
Inclusion bodies were isolated from the recombinant E.
coli strain BL21(DE3) [pPHL36] and were solubilized as
described earlier [37]. A solution (25 ml) containing 50
mM Tris hydrochloride, pH 7.2, 0.5 mM DTT and solubi-
lized protein was passed through a column of Q Sepha-
rose Fast Flow (2 × 18 cm, Amersham Pharmacia Biotech,
Freiburg, Germany) (flow rate, 1 ml min-1). The column
was washed with 100 ml of 50 mM Tris hydrochloride, pH
7.2, containing 0.5 mM DTT and was then developed with
a linear gradient of 0 – 0.5 M NaCl in the same buffer
(total volume, 280 ml). Lumazine protein was eluted
from 220 to 260 ml. The enzyme fraction was dialyzed
against 50 mM sodium/potassium phosphate, pH 7.0,
containing 5 mM 2-mercaptoethanol. The solution was
centrifuged for 30 min at 26,000× g, and the supernatant
was passed through a column of Superdex 75 (2.6 × 60
cm, Amersham Pharmacia Biotech, Freiburg, Germany)
(flow rate, 3 ml min-1). The column was developed with
360 ml of 50 mM phosphate, pH 7.0, containing 5 mM
DTT. The enzyme was eluted from 180 to 200 ml. Frac-
tions were combined and concentrated by ultrafiltration.
Estimation of protein concentration
Protein concentration was estimated by a modified Brad-
ford procedure [38].
SDS polyacrylamide gel electrophoresis
Sodium dodecyl sulfate polyacrylamide gel electrophore-
sis was performed with 16 % polyacryl-amide gels by pub-
lished procedures [39]. Molecular weight standards were
supplied by Sigma (Munich, Germany).
Protein sequencing
Sequence determination was performed by the automated
Edman method using a 471 A Protein Sequencer (Perkin
Elmer).
Steady state kinetics
Assay mixtures containing 100 mM phosphate, pH 7.2, 10
mM EDTA, 10 mM sodium sulfite, 0.6 mM 6,7-dimethyl-
Table 3: Steady state kinetic analysis of wild type and mutant riboflavin synthases
enzyme vmax [nmol mg-1 min-1]K M [µM]
wild type 158 ± 2.9 5.7 ± 0.24
S146A 183 ± 9.5 3.8 ± 0.40
S146C 179 ± 7.0 8.9 ± 1.06
C48S 27 ± 1 1.1 ± 0.13
C48A < 0.1
C48M < 0.1BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
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8-ribityllumazine, and protein were incubated at 37°C.
Formation of riboflavin was monitored photometrically
at 470 nm. The absorbance coefficient for riboflavin is
9,100 M-1 cm-1 at 470 nm [7,40].
Analytical ultracentrifugation
Boundary sedimentation and sedimentation equilibrium
experiments were performed using an analytical ultracen-
trifuge Optima XL-I from Beckman Instruments (Palo
Alto, CA) equipped with absorbance and interference
optics. Aluminum double sector cells equipped with sap-
phire windows were used throughout. Protein solutions
were dialyzed against 20 mM potassium phosphate, pH
7.0, containing 100 mM potassium chloride. The partial
specific volume was estimated from the amino acid com-
position yielding a value of 0.73 ml g-1 [41]. Sedimenta-
tion equilibrium experiments were performed with a
solution containing 20 mM potassium phosphate, pH
7.0, 100 mM potassium chloride, and protein (0.7 mg ml-
1). Samples were centrifuged at 11,000 rpm and 4°C for
72 h. Protein concentration was monitored photometri-
cally at 280 nm. For boundary sedimentation experiments
the protein (1.6 mg ml-1) was centrifuged at 55,000 rpm
and 20°C for 2 h. Protein concentration was monitored
interferometrically at intervals of 10 min.
Electrospray mass spectrometry
Experiments were performed with a triple quadrupol ion
spray mass spectrometer API365 (SciEx, Thornhill,
Ontario, Canada) [42].
NMR spectroscopy
19F NMR spectra were recorded at 470 MHz using an
AVANCE 500 MHz spectrometer from Bruker Instruments
(Karlsruhe, Germany) equipped with a 19F probehead.
Experimental parameters were as follows: pulse angle, 70°
(10 µsec); repetition rate, 3 sec; 64 K data set; 500 to
20,000 scans. Chemical shifts were referenced to an exter-
nal standard containing 50 mM sodium trifluoroacetate,
pH 7.0. Measurements were performed at 11 °C. Samples
contained 20 mM phosphate, pH 7.0, and 100 mM potas-
sium chloride in 10 % D2O.
Authors contributions
The study was designed and coordinated by MF and AB.
The study was performed as follows: AKS, BI, KK, MF, WE
contributed to the NMR part of the manuscript. MF
cloned and overexpressed the protein. RF, AKS purified
the protein. MC synthezised the ligands used in this study.
BI constructed the mutant proteins. SS, SG, RH, GR partic-
ipated in the discussion of the study.
Acknowledgements
This work was supported by grants from the Deutsche Forschungsgemein-
schaft and the Fonds der Chemischen Industrie. We thank Angelika 
Werner for expert help with the preparation of the manuscript, Peter Köh-
ler for protein sequencing, Lars Schulte for skillful assistance and Adolphus 
van Loon for plasmids. Mark Cushman is grateful for the support afforded 
by NIH Grant GM51469.
References
1. Bandrin SV, Beburov MI, Rabinovich PM, Stepanov A: Riboflavin
auxotrophs of Escherichia coli. Genetika 1979, 15:2063-2065.
2. Wang A: Isolation of vitamin B2 auxotrophs and preliminary
genetic mapping in Salmonella typhimurium. Yi Chuan Xue Bao
1992, 19:362-368.
3. Oltmanns O, Lingens F: Isolation of riboflavin-deficient mutants
of Saccharomyces cerevisiae. Z Naturforsch 1967, B22:751-754.
4. Logvinenko EM, Shavlovskii GM, Koltun LV: Preparation and prop-
erties of riboflavin-dependent mutants of Pichia guilliermon-
dii Wickerham yeasts. Mikrobiologiia 1972, 41:1103-1104.
5. Plaut GWE: Studies on the nature of the enzymic conversion
of 6,7-dimethyl-8-ribityllumazine to riboflavin.  J Biol Chem
1963, 238:2225.
6. Harvey RA, Plaut GWE: Riboflavin synthase from yeast: Proper-
ties of complexes of the enzyme with lumazine derivatives
and riboflavin. J Biol Chem 1966, 241:2120-2136.
7. Plaut GWE., Beach RL, Aogaichi T: Studies on the mechanism of
elimination of protons from the methyl groups of 6,7-dime-
thyl-6-ribityllumazine by riboflavin synthetase.  Biochemistry
1970, 9:771-785.
8. Beach RL, Plaut GWE: Stereospecificity of the enzymic synthe-
sis of the o-xylene ring of riboflavin.  J Am Chem Soc 1970,
92:2913-2916.
9. Paterson T, Wood HC: Deuterium exchange of C-methyl pro-
tons in 6,7-dimethyl-8-D-ribityllumazine, and studies of the
mechanism of riboflavin biosynthesis. J Chem Soc Chem Commun
1969:290-291.
10. Sedlmaier H, Müller F, Keller PJ, Bacher A: Enzymatic synthesis of
riboflavin and FMN specifically labeled with 13C in the xylene
ring. Z Naturforsch 1987, 42c:425-429.
11. Illarionov B, Eisenreich W, Bacher A: A pentacyclic reaction
intermediate of riboflavin synthase. Proc Natl Acad Sci USA 2001,
98:7224-7229.
12. Bacher A, Baur R, Eggers K, Harders H, Otto MK, Schnepple H: Ribo-
flavin synthases of Bacillus subtilis. Purification and
properties. J Biol Chem 1980, 255:632-637.
13. Eberhardt S, Richter G, Gimbel W, Werner T, Bacher A: Cloning,
sequencing, mapping and hyperexpression of the ribC gene
coding for riboflavin synthase of Escherichia coli. Eur J Biochem
1996, 242:712-719.
14. Schott K, Kellermann J, Lottspeich F, Bacher A: Riboflavin syn-
thases of Bacillus subtilis. Purification and amino acid
sequence of the α subunit. J Biol Chem 1990, 265:4204-4209.
15. Liao DI, Wawrzak Z, Calabrese JC, Viitanen PV, Jordan DB: Crystal
structure of riboflavin synthase. Structure 2001, 9:399-408.
16. Eberhardt S, Zingler N, Kemter K, Richter G, Cushman M, Bacher A:
Domain structure of riboflavin synthase. Eur J Biochem 2001,
268:4315-4323.
17. Truffault V, Coles M, Diercks T, Abelmann K, Eberhardt S, Lüttgen H,
Bacher A, Kessler H: The solution structure of the N-terminal
domain of riboflavin synthase. J Mol Biol 2001, 309:949-960.
18. Illarionov B, Kemter K, Eberhardt S, Richter G, Cushman M, Bacher
A:  Riboflavin synthase of Escherichia coli. Effect of single
amino acid substitutions on reaction rate and ligand binding
properties. J Biol Chem 2001, 276:11524-11530.
19. Cushman M, Patrick DA, Bacher A, Scheuring J: Synthesis of
epimeric 6,7-bis(trifluoromethyl)-8-ribityllumazine
hydrates. Stereoselective interaction with the light ribofla-
vin synthase of Bacillus subtilis. J Org Chem 1991, 56:4603-4608.
20. Cushman M, Patel HH, Scheuring J, Bacher A: F NMR Studies on
the mechanism of riboflavin synthase. Synthesis of 6-(Trif-
luoromethyl)-7-oxo-8-(D-ribityl)lumazine and 6-(Trifluor-
omethyl)-7-methyl-8-(D-ribityl)lumazine.  J Org Chem 1992,
57:5630-5643.
21. Gerhardt S, Schott A, Kairies N, Cushman M, Illarionov B, Eisenreich
W, Bacher A, Huber R, Steinbacher S, Fischer M: Studies on the
reaction mechanism of riboflavin synthase. X-ray crystal
structure of a complex with 6-carboxyethyl-7-oxo-8-ribityl-
lumazine. Structure (Camb) 2002, 10:1371-1381.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/18
Page 19 of 19
(page number not for citation purposes)
22. Otto MK, Bacher A: Ligand-binding studies on light riboflavin
synthase from Bacillus subtilis. Eur J Biochem 1981, 115:511-517.
23. Scheuring J, Fischer M, Cushman M, Lee J, Bacher A, Oschkinat H:
NMR analysis of site-specific binding in oligomeric proteins.
Dynamic studies on the interaction of riboflavin synthase
with trifluoromethyl-substituted intermediates.  Biochemistry
1996, 35:9637-9646.
24. Scheuring J, Lee J, Cushman M, Oschkinat H, Bacher A: 19F NMR
studies on lumazine protein from Photobacterium
phosphoreum. In: Flavins and Flavoproteins 1994:75-78.
25. Scheuring J, Lee J, Cushman M, Oschkinat H, Patel H, Patrick DA,
Bacher A: Trifluoromethyllumazine derivatives as 19F NMR
probes for lumazine protein. Biochemistry 1994, 33:7634-40.
26. Goetz JM, Poliks B, Studelska DR, Fischer M, Kugelbrey K, Bacher A,
Cushman M, Schäfer J: Investigation of the binding of fluor-
olumazines to the 1-MDa capsid of lumazine synthase by
15N{19F} REDOR NMR. J Am Chem Soc 1999, 121:7500-7508.
27. Metha AK, Studelska DR, Fischer M, Giessauf A, Kemter K, Bacher A,
Cushman M, Schaefer J: Investigation of the binding of epimer A
of the covalent hydrate of 6,7-bis(trifluoromethyl)-8-D-ribit-
yllumazine to a recombinant F22W Bacillus subtilis lumazine
synthase mutant by 15N{19F}REDOR NMR. J Org Chem 2002,
67:2087-2092.
28. Gast R, Neering IR, Lee J: Separation of a blue fluorescence pro-
tein from bacterial luciferase. Biochem Biophys Res Commun 1978,
80:14-21.
29. O'Kane DJ, Lee J: Physical characterization of lumazine pro-
teins from Photobacterium. Biochemistry 1985, 24:1484-1488.
30. Bacher A, Neuberger G, Volk R: Enzymatic synthesis of 6,7-
dimethyl-8-ribityllumazine. In: Chemistry and Biology of Pteridines
1986:227-230.
31. Wood HC, Wrigglesworth R, Yeowell DA, Gurney FW: Specific
enzyme inhibitors in vitamin biosynthesis. II. Revised struc-
tures for some 8-substituted pyrido(2,3-d)-pyrimidines.  J
Chem Soc 1974, 11:1225-30.
32. Al-Hassan SS, Kuhol RJ, Livingstone DB, Suckling CJ, Wood HCS,
Wrigglesworth R, Ferone R: Specific enzyme inhibitors in vita-
min biosynthesis. Part 3. The synthesis and inhibitory prop-
erties of some substrate and transition state analogs of
riboflavin synthase. J Chem Soc Perkin Trans I 1980:2645-2656.
33. Fischer M, Haase I, Feicht R, Richter G, Gerhardt S, Changeux JP,
Huber R, Bacher A: Biosynthesis of Riboflavin. 6,7-Dimethyl-8-
ribityllumazine synthase of Schizosaccharomyces pombe. Eur J
Biochem 2002, 269:519-26.
34. Bullock WO, Fernandez JM, Short JM: XL1-blue: a high efficiency
plasmid transforming recA Escherichia coli strain with β-
galactosidase selection. BioTechniques 1987, 5:376-379.
35. Sanger F, Niklen S, Coulson AR: DNA sequencing with chain-ter-
minating inhibitors. Proc Natl Acad Sci USA 1977, 74:5463-5467.
36. Stüber D, Matile H, Garotta G: System for high-level production
in Escherichia coli and rapid purification of recombinant pro-
teins: application to epitop mapping, preparation of antibod-
ies, and structure-function analysis. In: Immunological Methods
1990, IV:121-152.
37. Illarionov B, Illarionova V, Lee J, van Dongen W, Vervoort J: Expres-
sion and properties of the recombinant lumazine (riboflavin)
protein from Photobacterium leiognathi. Biochem Biophys Acta
1994, 1201:251-258.
38. Read SM, Northcote DH: Minimization of variation in the
response to different proteins of the Coomassie blue G dye-
binding assay for protein. Anal Biochem 1981, 116:53-64.
39. Läemmli UK: Cleavage of structural proteins during the
assembly of the head of bacteriophage T4.  Nature 1970,
227:680-685.
40. Plaut GWE, Harvey RA: The enzymic synthesis of riboflavin. In:
Methods Enzymol 1971, 18B:515-538.
41. Laue TM, Shah BD, Ridgeway TM, Pelletier SL: In: Analytical ultracen-
trifugation in biochemistry and polymer science. Edited by: Harding SE,
Rowe AJ, Horton JC. Royal Society of Chemistry, Cambridge; 1992:90-125. 
42. Mann M, Wilm M: electrospray mass spectrometry for protein
characterization. Trends Biochem Sci 1995, 20:219-224.
43. Zamenhof PJ, Villarejo M: Construction and properties of
Escherichia coli strains exhibiting α-complementation of β-
galactosidase fragments in vivo. J Bacteriol 1972, 110:171-178.
44. Studier FW: Use of bacteriophage T7 lysozyme to improve an
inducible T7 expression system. J Mol Biol 1991, 219:37-44.
45. Tabor S: Expression using the T7 RNA polymerase/promoter
system. In: Current Protocols of Molecular Biology Green Publishing and
Wiley Interscience, NY; 1990:1621. 